Medifast (NYSE:MED) Updates Q2 2025 Earnings Guidance

Medifast (NYSE:MED) updated its second quarter 2025 earnings guidance on Monday. The company provided EPS guidance of -0.550-0.000 for the period, compared to the consensus EPS estimate of -0.070. The company issued revenue guidance of $85.0 million-$105.0 million, compared to the consensus revenue estimate of $112.3 million.

Analysts Set New Price Targets

Separately, DA Davidson cut their price objective on Medifast from $17.00 to $16.50 and set a “neutral” rating for the company in a research report on Wednesday, February 19th.

Medifast Trading Down 4.2 %

Shares of NYSE:MED traded down $0.53 on Tuesday, reaching $12.05. The company had a trading volume of 44,772 shares, compared to its average volume of 318,981. The firm has a market capitalization of $131.80 million, a PE ratio of 66.94 and a beta of 1.05. Medifast has a 52-week low of $11.57 and a 52-week high of $36.30. The firm’s 50 day simple moving average is $13.51 and its 200-day simple moving average is $16.10.

Medifast (NYSE:MED) last released its earnings results on Monday, April 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). The company had revenue of $115.73 million for the quarter, compared to analysts’ expectations of $114.85 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%. As a group, equities research analysts predict that Medifast will post 0.51 earnings per share for the current year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.